Enovis Co. (NYSE:ENOV) Holdings Raised by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC lifted its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 25.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 201,652 shares of the company's stock after buying an additional 41,089 shares during the period. Chartwell Investment Partners LLC owned approximately 0.36% of Enovis worth $8,681,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Diamond Hill Capital Management Inc. lifted its stake in shares of Enovis by 7.8% during the third quarter. Diamond Hill Capital Management Inc. now owns 3,004,694 shares of the company's stock worth $129,352,000 after purchasing an additional 218,660 shares in the last quarter. American Century Companies Inc. lifted its position in Enovis by 78.6% during the 2nd quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock worth $68,337,000 after acquiring an additional 665,208 shares in the last quarter. River Road Asset Management LLC purchased a new stake in shares of Enovis during the third quarter valued at approximately $51,341,000. Magnetar Financial LLC raised its stake in shares of Enovis by 66.7% during the second quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock valued at $49,937,000 after purchasing an additional 442,051 shares during the period. Finally, Tributary Capital Management LLC lifted its position in shares of Enovis by 3.3% during the third quarter. Tributary Capital Management LLC now owns 422,831 shares of the company's stock worth $18,203,000 after purchasing an additional 13,641 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Trading Up 1.7 %

Shares of NYSE ENOV traded up $0.77 during midday trading on Monday, hitting $47.19. The company's stock had a trading volume of 200,871 shares, compared to its average volume of 582,559. The company has a current ratio of 2.27, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03. The firm's fifty day moving average price is $42.23 and its 200-day moving average price is $45.43.

Enovis (NYSE:ENOV - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to the consensus estimate of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's quarterly revenue was up 21.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.56 earnings per share. On average, equities research analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $65.00 price objective on shares of Enovis in a report on Thursday. JMP Securities began coverage on Enovis in a report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price target for the company. Evercore ISI dropped their price objective on Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. cut their price target on shares of Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Enovis presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.